Key Highlights

  • Loss per share was USD 0.91 against an estimate of a USD 0.80 loss.
  • Net loss was USD 15.62 million, against USD 24.78 million a year earlier.
  • Research and development expenses were USD 11.27 million, against USD 15.16 million.
  • General and administrative expenses were USD 6.04 million, against USD 11.04 million.

ImageneBio (NASDAQ:IMA) reported a third quarter 2026 loss per share of USD 0.91, against an estimate of a USD 0.80 loss. Net loss was USD 15.62 million, compared with USD 24.78 million in the third quarter of 2025.

The loss from operations was USD 17.31 million, against USD 26.19 million a year earlier. The company reported the figures in its quarterly filing for the period ended September 30, 2026.

Operating Expenses

Research and development expenses were USD 11.27 million, compared with USD 15.16 million. General and administrative expenses were USD 6.04 million, compared with USD 11.04 million. Total operating expenses were USD 17.31 million, against USD 26.19 million.

The filing reports share-based compensation within Research and Development expenses of USD 270 thousand, compared with USD 10,005 thousand a year earlier, and within general and administrative expenses of USD 1,395 thousand, compared with USD 5,278 thousand.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 36.42 million, compared with USD 38.44 million. Total operating expenses were USD 41.17 million, against USD 40.35 million, and the loss from operations was USD 41.17 million, against USD 39.55 million.

Research and development expenses for the nine months were USD 23.90 million, against USD 24.85 million, and general and administrative expenses were USD 17.27 million, against USD 15.50 million.

Merger, Income and Related Party Items

The filing states that Assets acquired in the Merger included USD 94.7 million of cash, cash equivalents and marketable securities. Interest income, net, consists of interest earned on cash, cash equivalents and marketable securities, and other income, net, consisted primarily of sublease income.

The filing also describes a Promissory Note receivable from BuyCo, under which no interest was received through September 30, 2026. Any payments received under the note are distributed to Legacy Inmagene contingent value right holders. Since July 25, 2025, the company has received reimbursement of expenses for agreed research and development activities from a related party where one of its board members is a partner, recorded as an offset to research and development expenses.

As of September 30, 2026, the company had cash, cash equivalents and marketable securities of USD 126.6 million and an accumulated Deficit of USD 266.5 million. The company believes these resources are sufficient to support operations for at least the next 12 months from the date of issuance of its condensed consolidated financial statements. The filing identifies olevaprubart as its product candidate and lists the timing of planned or ongoing clinical trials, including data readouts, among its forward-looking topics.

ImageneBio Q3 2026 Earnings: Key Takeaways

ImageneBio reported a third quarter 2026 loss per share of USD 0.91 and a net loss of USD 15.62 million. Research and development expenses were USD 11.27 million, and general and administrative expenses were USD 6.04 million.